강아지 임신중절약 (아글레프리스톤)
Aglepristone
RU-534
다른 이름: Alizine · RU-534 · RU46534 · RU-46534
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| To terminate pregnancy (up to day 45) | 10 mg/kg (0.33 mL/kg) subcutaneous injection only. Repeat one time, 24 hours after the first injection. | SC | q24h | 2 doses | 🌎 NA |
| To induce parturition | At day 60 (post-estimated LH surge): 15 mg/kg SC and another dose 24 hours later. Subsequently, give oxytocin 0.15 Units/kg SC at hourly intervals until last pup is delivered. | SC | q24h | 2 doses | 🌎 NA |
| To induce parturition | On or after day 58 of pregnancy: 15 mg/kg subcutaneously; repeat in 9 hours. | SC | Repeat in 9 hours | 2 doses | 🌎 NA |
| As an adjunct to treating pyometra/metritis (preserve fertility) | Treatment begun at week 2-4 of diestrus with a single SC injection of aglepristone at 10 mg/kg. Doses are repeated at days 2, 7, and 14. | SC | Days 1, 2, 7, 14 | 14 days | 🌎 NA |
| For closed cervix pyometra | 6 mg/kg twice daily on the first day followed by the same dose once daily on days 2, 3, and 4. Some prefer using larger doses (10mg/kg) once daily on days 1, 3, and 8, then follow up also on days 15 and 28 depending on the bitch's condition. | SC | Variable | Variable | 🌎 NA |
| For metritis | 10 mg/kg subcutaneously once daily on days 1, 2 and 8. | SC | Days 1, 2, 8 | 8 days | 🌎 NA |
| For open or closed pyometra | aglepristone 10 mg/kg subcutaneously once daily on days 1, 2 and 8 and cloprostenol 1 microgram/kg subcutaneously on days 3 to 7. | SC | Days 1, 2, 8 | 8 days | 🌎 NA |
| For pyometra | 10 mg/kg SC on days 1, 2, 8, 15, & 29. Give misoprostol 10 micrograms/kg PO twice daily on days 3 through 12. | SC | Days 1, 2, 8, 15, 29 | 29 days | 🌎 NA |
| Pregnancy termination | 10 mg/kg | SC | q24h | 2 doses | 🌍 EU |
| Progesterone-induced acromegaly | 10 mg/kg | SC | q24h for 2 doses, then q7d | 5 doses total | 🌍 EU |
| Pyometra | 10 mg/kg | SC | Days 1, 2, and 7 | 3 doses (up to 5) | 🌍 EU |
- To terminate pregnancy (up to day 45): A maximum of 5 mL should be injected at any one site. Light massage of the injection site is recommended.
- To induce parturition: Additional studies confirming efficacy and safety are warranted before routine clinical application.
- To induce parturition: Expulsion of first pup occurred between 32 and 56 hours after treatment. Use standard protocols to assist with birth.
- As an adjunct to treating pyometra/metritis (preserve fertility): During first 7 days, daily injections of amoxicillin/clavulanic acid were also given.
- For open or closed pyometra: Bitches with closed pyometra or with elevated temperature/dehydration should also receive IV fluids and antibiotics. If unresolved, additional doses on days 14 and 28.
- For pyometra: Approximately 75% of cases show significant clinical improvement without developing adverse effects associated with prostaglandins.
- Pregnancy termination: Maximum of 5 ml injected at any one site.
- Progesterone-induced acromegaly: Maximum of 5 ml injected at any one site.
- Pyometra: Maximum of 5 ml injected at any one site. Additional doses may be given on days 14 and 21 if there is an inadequate response.
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| For treating mammary fibroadenomatous hyperplasia | 20 mg/kg aglepristone subcutaneously once weekly until resolution of signs. | SC | q7d | Until resolution | 🌎 NA |
| For treating mammary fibroadenomatous hyperplasia | 10 mg/kg SC on two consecutive days, once weekly. | SC | Two consecutive days weekly | 3-5 weeks | 🌎 NA |
| To terminate pregnancy (up to day 45) | 15 mg/kg SC twice 24 hours apart. | SC | q24h | 2 doses | 🌎 NA |
| Pregnancy termination | 15 mg/kg | SC | q24h | 2 doses | 🌍 EU |
| Fibroadenomatous hyperplasia | 20 mg/kg | SC | q7d | Until resolution | 🌍 EU |
| Pyometra | 15 mg/kg | SC | Days 1, 2, and 7 | 3 doses (up to 5) | 🌍 EU |
- For treating mammary fibroadenomatous hyperplasia: Cats with HR > 200 BPM should receive atenolol at 6.25 mg (total dose) until HR < 200 BPM with regression in mammary gland size.
- For treating mammary fibroadenomatous hyperplasia: Complete regression occurs on average 3-4 weeks. Relapses can occur, particularly if treated with long-acting progestins; these cats should be treated for 5 weeks.
- To terminate pregnancy (up to day 45): Efficacy is 95% if administered before implantation, 85% if after implantation. Termination occurs within 3 days in 50% of queens.
- Pregnancy termination: Maximum of 5 ml injected at any one site.
- Fibroadenomatous hyperplasia: Maximum of 5 ml injected at any one site. Consider atenolol if cat is tachycardic with heart rate >200 bpm.
- Pyometra: Maximum of 5 ml injected at any one site. Additional doses may be given on days 14 and 21 if there is an inadequate response.
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
아글레프리스톤은 프로게스테론 수용체 길항제로 작용하는 합성 스테로이드입니다. 주로 수의학에서 개와 고양이의 임신 중절, 그리고 자근축농증과 고양이의 섬유선종성 유선 증식증의 내과적 치료에 사용됩니다.
오일-알코올 기반 제제이므로 국소적인 주사 부위 반응이 흔하게 발생합니다.
임상 요점: 경쟁적 길항제로서 아글레프리스톤은 체내 프로게스테론 수치를 낮추지 않고, 수용체 수준에서 직접 생물학적 작용을 차단합니다.
작용 기전
Aglepristone competitively binds to progesterone (P4) receptors in the uterus and other target tissues.
- In dogs, its affinity for uterine progesterone receptors is ~3x that of endogenous progesterone; in queens, it is ~9x greater.
- Pathway: Aglepristone binding → blockade of progesterone signaling → withdrawal of pregnancy support → cervical dilation and resumption of myometrial contractility → fetal resorption or abortion (usually within 7 days).
- It also binds to glucocorticoid receptors acting as an antagonist, which can block endogenous or exogenously administered glucocorticoids from acting at these sites.
안전성·주의사항
금기사항
- Known hypersensitivity to aglepristone
- Pregnancy (unless used specifically for pregnancy termination or inducing parturition)
- Hypoadrenocorticism (Addison's disease) or genetic predisposition to it
- Peritonitis (must be ruled out before using for pyometra)
- Caution in patients with poor health, diabetes, or impaired hepatic/renal function
부작용
- Injection site reactions (pain, edema, skin thickening, ulceration, localized lymph node enlargement)
- Anorexia (25%)
- Excitation (23%)
- Depression (21%)
- Diarrhea (13%)
- Uterine infections (3.4%)
- Vomiting (2%)
- Brown mucoid vaginal discharge (associated with pregnancy termination)
- Mammary gland congestion
주의
WARNING: Accidental injection of this product can induce abortion; it should not be administered or handled by pregnant women. Accidental injection can also cause severe pain, intense swelling, and ischemic necrosis that can lead to serious sequelae, including loss of a digit. Seek prompt medical attention if accidentally injected.
- Injection Site Care: Light massage of the injection site is recommended after administration. Larger dogs should not receive more than 5 mL at any one SC injection site. Administering into the scruff of the neck may help avoid severe injection reactions.
- Pyometra: When used for pyometra, there is a substantial risk of treatment failure, and ovariohysterectomy may ultimately be required.
약물 상호작용
Could reduce the efficacy of aglepristone
Aglepristone could reduce the efficacy of glucocorticoid treatment due to receptor antagonism
May interact with aglepristone (manufacturer warning, likely due to CYP450 enzyme inhibition)
May interact with aglepristone (manufacturer warning)
May interact with aglepristone (manufacturer warning)
모니터링
- Clinical efficacy
- For pregnancy termination: ultrasound 10 days after treatment and at least 30 days after mating
- Injection site reactions (pain, swelling, ulceration)
- Systemic adverse effects (anorexia, excitation, depression, diarrhea)
약동학
반감기
흡수
In dogs, after injecting two doses of 10 mg/kg 24 hours apart, peak serum levels occur about 2.5 days later.
분포
Highly lipophilic, distributes widely into tissues.
대사
Hepatic metabolism is likely, given potential interactions with CYP450 inhibitors like ketoconazole.
배설
The majority (90%) of the drug is excreted via the feces.
과다투여
When administered at 3X (30 mg/kg) recommended doses, bitches demonstrated no untoward systemic effects. Localized reactions were noted at the injection site, presumably due to the larger volumes injected.
제품
제형
- Injectable solution (30 mg/mL)
동물용의약품
- Aglepristone 30 mg/mL in 5 mL & 10 mL vials (Alizine® or Alizin®)
규제 현황
Authorized in multiple EU member states.
POM-V classification.
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Aglepristone injection should be stored below 25°C and protected from light. The manufacturer recommends using the product within 28 days of withdrawing the first dose. Due to the product's oil/alcohol vehicle formulation, it should not be mixed with any other medication.
보호자 정보
- 수의사 투여 전용: 인체에 잘못 주사될 경우 심각한 위험이 있으므로, 이 제품은 수의학 전문가만 취급하고 투여해야 합니다.
- 임신 중절: 암개의 임신 중절을 위해 사용할 경우, 교배 후 26~45일 사이에 사용 시 성공률은 약 95%임을 인지하셔야 합니다.
- 질 분비물: 태아 배출 약 24시간 전에 갈색의 점액성 질 분비물이 관찰될 수 있습니다.
- 부작용: 치료 후 반려동물에게 식욕 부진, 흥분, 불안 또는 우울, 구토, 설사 등의 증상이 나타날 수 있습니다.
- 수의사에게 연락해야 할 때: 치료 후 화농성(고름) 또는 출혈성 분비물이 보이거나, 질 분비물이 3주 이상 지속되면 수의사에게 연락하십시오.
- 자궁축농증 치료: 자궁축농증 치료에 사용할 경우 치료 실패의 위험이 상당하며, 결국 외과적 수술(난소자궁적출술/중성화)이 필요할 수 있습니다.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.